<DOC>
	<DOCNO>NCT00920257</DOCNO>
	<brief_summary>This study first time human , Phase I , open-label , dose-escalation study oral AKT inhibitor GSK2141795 subject solid tumor lymphomas .</brief_summary>
	<brief_title>A Phase I , Open-Label , First-Time-In-Human Study Oral AKT Inhibitor GSK2141795</brief_title>
	<detailed_description />
	<criteria>Capable give write informed consent , include compliance requirement restriction list consent form . Male female , 18 year old . Histologically cytologically confirm diagnosis solid tumor malignancy lymphoma responsive standard therapy approve curative therapy . Subjects malignancy relate human immunodeficiency virus ( HIV ) solid organ transplant exclude . Performance Status score 0 1 accord Eastern Cooperative Oncology Group ( ECOG ) scale . Able swallow retain oral medication . Fasting serum glucose &lt; 126 mg/dL . Male subject female partner childbearing potential must prior vasectomy agree use adequate contraception time first dose GSK2141795 three month last dose GSK2141795 . A female subject eligible participate nonchild bear potential , childbearing potential willing use adequate birth control Adequate organ function ( Part 2 endometrial ) Histologically cytologically confirm diagnosis relapse metastatic endometrial cancer . ( Part 2 endometrial ) No two prior cytotoxic chemotherapy regimen relapse metastatic setting . Targeted agent like bevacizumab consider cytotoxic chemotherapy purpose study ( Part 2 , breast ) Histologically cytologically confirm diagnosis locally advance metastatic breast cancer . ( Part 2 , breast ) No three prior cytotoxic chemotherapy regimen metastatic setting . Targeted agent like lapatinib , bevacizumab , trastuzumab consider cytotoxic chemotherapy purpose study Chemotherapy , radiotherapy , immunotherapy within 28 day ( 42 day prior nitrosoureas mitomycin C ) prior first dose GSK2141795 . Chemotherapy regimens give continuously weekly basis limit potential delayed toxicity permit approval GSK Medical Monitor dose chemotherapy terminate least 14 day prior first dose GSK2141795 . Use investigational anticancer drug within 28 day five halflives , whichever longer , precede first dose GSK2141795 . Current use prohibit medication require medication treatment GSK2141795 . Current use anticoagulant therapeutic level within seven day prior first dose GSK2141795 , include warfarin , low molecular weight heparin direct thrombin inhibitor . Low dose ( prophylactic ) anticoagulant warfarin , low molecular weight heparin , selective Factor Xa inhibitor direct thrombin inhibitor permit provide subject 's PT PTT meet entry criterion . Presence active gastrointestinal disease condition could affect gastrointestinal absorption ( e.g . malabsorption syndrome ) predispose subject gastrointestinal ulceration . Current use antiplatelet agent ( e.g . dipyridamole , clopidogrel ) aspirin ( 81 mg daily ) . Any major surgery within last four week screen . Unresolved toxicity ( except alopecia ) great equal Grade 2 previous anticancer therapy unless agree GSK Medical Monitor investigator , GSK Medical Monitor investigator consider ongoing toxicity introduce additional risk factor interfere study procedure . Previously diagnose diabetes mellitus ( type 1 2 ) . Current use oral corticosteroid , exception inhale topical corticosteroid . History allogeneic stem cell transplant . Subjects history autologous stem cell transplant NOT exclude . Any serious unstable preexist medical , psychiatric , condition ( include lab abnormality ) could interfere subject safety obtain informed consent . Symptomatic untreated CNS metastasis leptomeningeal involvement . Subjects previously treat condition , asymptomatic without antiepileptic medication steroid least 2 month eligible . Subjects primary brain tumor exclude . Evidence severe uncontrolled systemic disease ( e.g. , unstable uncompensated respiratory , hepatic , renal , cardiac disease ) . QTc interval great equal 470 msec . Other clinically significant ECG abnormality include 2nd degree ( type II ) 3rd degree atrioventricular ( AV ) block . History myocardial infarction , acute coronary syndrome ( include unstable angina ) , coronary angioplasty , stenting bypass graft within past 6 month . Class III IV heart failure define New York Heart Association ( NYHA ) functional classification system . Pregnant Lactating female . History HIV infection ; history hepatitis B C ( subject evidence clear hepatitis B eligible )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>lymphoma</keyword>
	<keyword>breast cancer</keyword>
	<keyword>oncology</keyword>
	<keyword>solid tumor</keyword>
	<keyword>AKT inhibitor</keyword>
	<keyword>endometrial cancer</keyword>
	<keyword>first time human</keyword>
	<keyword>GSK2141795</keyword>
</DOC>